IL2 and renal carcinoma: NFAT proteins were first discovered in T cells in the 1980s, as transcriptional activators of interleukin-2 (IL2), a key regulator of T cell immune response, that at the time was also successfully introduced into practice as immune therapy for some renal cancers and malignant melanoma [59, 60].